PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma
<i>PIK3CA</i> mutations are more common in EOAC and independently associated with worse OS. These findings suggest incorporating <i>PIK3C</i>A mutation status into prognostic assessments and warrant further investigation of <i>PIK3CA</i> inhibitors as a potential therapeutic strategy for appendiceal adenocarcinoma.
Authors
- Rushabh Gujarathi (ORCID: https://orcid.org/0000-0002-1748-6508)
- Princy Gupta (ORCID: https://orcid.org/0000-0002-5578-1647)
- Jason M. Sheltzer
- Samuel D. Butensky (ORCID: https://orcid.org/0000-0002-6354-8124)
- Elizabeth L. Godfrey (ORCID: https://orcid.org/0000-0002-9258-4706)
- Raghav Prashant Sundar (ORCID: https://orcid.org/0000-0001-7565-4269)
- Justin M Bader
- Lu Qiao
- Kurt S. Schultz
- Ardaman Shergill
- Kiran K. Turaga
Institutions
- University of Louisville (US)
- Yale University (US)
- University of Chicago (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1200/po-25-00741
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00